# John Vissing

## List of Publications by Year in descending order



| | | | |
|---|---|---|---|
| 401 papers | 13,895 citations | 23879 60 h-index | 45040 94 g-index |
| 413 all docs | 413 docs citations | 413 times ranked | 11599 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Paternal Inheritance of Mitochondrial DNA. New England Journal of Medicine, 2002, 347, 576-580. | 13.9 | 595 |
| 2 | Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurology, The, 2017, 16, 976-986. | 4.9 | 472 |
| 3 | Recombination of Human Mitochondrial DNA. Science, 2004, 304, 981-981. | 6.0 | 253 |
| 4 | The spectrum of exercise tolerance in mitochondrial myopathies: a study of 40 patients. Brain, 2003, 126, 413-423. | 3.7 | 226 |
| 5 | The Effect of Oral Sucrose on Exercise Tolerance in Patients with McArdle's Disease. New England Journal of Medicine, 2003, 349, 2503-2509. | 13.9 | 215 |
| 6 | High prevalence and phenotypeÃ¢Â€Â“genotype correlations of limb girdle muscular dystrophy type 2I in Denmark. Annals of Neurology, 2006, 59, 808-815. | 2.8 | 201 |
| 7 | McArdle disease: a clinical review. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1182-1188. | 0.9 | 197 |
| 8 | Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2021, 20, 526-536. | 4.9 | 194 |
| 9 | Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy. Brain, 2006, 129, 3402-3412. | 3.7 | 184 |
| 10 | A nonischemic forearm exercise test for McArdle disease. Annals of Neurology, 2002, 52, 153-159. | 2.8 | 163 |
| 11 | Identification and Characterization of a Common Set of Complex I Assembly Intermediates in Mitochondria from Patients with Complex I Deficiency. Journal of Biological Chemistry, 2003, 278, 43081-43088. | 1.6 | 163 |
| 12 | Mitochondrial encephalomyopathy with elevated methylmalonic acid is caused by SUCLA2 mutations. Brain, 2007, 130, 853-861. | 3.7 | 162 |
| 13 | Longâ€term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle and Nerve, 2019, 60, 14-24. | 1.0 | 162 |
| 14 | Quantitative Muscle MRI as an Assessment Tool for Monitoring Disease Progression in LGMD2I: A Multicentre Longitudinal Study. PLoS ONE, 2013, 8, e70993. | 1.1 | 148 |
| 15 | Aerobic conditioning: An effective therapy in McArdle's disease. Annals of Neurology, 2006, 59, 922-928. | 2.8 | 146 |
| 16 | Cardiac manifestations of myotonic dystrophy type 1. International Journal of Cardiology, 2012, 160, 82-88. | 0.8 | 146 |
| 17 | Novel POLG mutations in progressive external ophthalmoplegia mimicking mitochondrial neurogastrointestinal encephalomyopathy. European Journal of Human Genetics, 2003, 11, 547-549. | 1.4 | 145 |
| 18 | Exercise-Induced Changes in Local Cerebral Glucose Utilization in the Rat. Journal of Cerebral Blood Flow and Metabolism, 1996, 16, 729-736. | 2.4 | 141 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Spontaneous "Second Wind" and Glucose-Induced Second "Second Wind" in McArdle Disease. Archives of Neurology, 2002, 59, 1395-402. | 4.9 | 138 |
| 20 | Aerobic training improves exercise performance in facioscapulohumeral muscular dystrophy. Neurology, 2005, 64, 1064-1066. | 1.5 | 124 |
| 21 | European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10â€year experience. European Journal of Neurology, 2017, 24, 768. | 1.7 | 118 |
| 22 | Mutation spectrum in the large GTPase dynamin 2, and genotype-phenotype correlation in autosomal dominant centronuclear myopathy. Human Mutation, 2012, 33, 949-959. | 1.1 | 115 |
| 23 | Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. Journal of the Neurological Sciences, 2020, 412, 116803. | 0.3 | 110 |
| 24 | Aerobic training in patients with myotonic dystrophy type 1. Annals of Neurology, 2005, 57, 754-757. | 2.8 | 102 |
| 25 | Muscle Glycogenosis Due to Phosphoglucomutase 1 Deficiency. New England Journal of Medicine, 2009, 361, 425-427. | 13.9 | 101 |
| 26 | Endurance training improves fitness and strength in patients with Becker muscular dystrophy. Brain, 2008, 131, 2824-2831. | 3.7 | 100 |
| 27 | Loss-of-function mutations inSCN4Acause severe foetal hypokinesia or â€˜classicalâ€™ congenital myopathy. Brain, 2016, 139, 674-691. | 3.7 | 100 |
| 28 | Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis. Neurology, 2021, 96, e853-e865. | 1.5 | 97 |
| 29 | Bezafibrate in skeletal muscle fatty acid oxidation disorders. Neurology, 2014, 82, 607-613. | 1.5 | 96 |
| 30 | A diagnostic cycle test for McArdle's disease. Annals of Neurology, 2003, 54, 539-542. | 2.8 | 93 |
| 31 | Congenital Titinopathy: Comprehensive characterization and pathogenic insights. Annals of Neurology, 2018, 83, 1105-1124. | 2.8 | 93 |
| 32 | Open-Label Trial of Anti-TNF-Î± in Dermato- and Polymyositis Treated Concomitantly with Methotrexate. European Neurology, 2008, 59, 159-163. | 0.6 | 92 |
| 33 | Leg muscle involvement in facioscapulohumeral muscular dystrophy assessed by MRI. Journal of Neurology, 2006, 253, 1437-1441. | 1.8 | 91 |
| 34 | Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurology, The, 2019, 18, 834-844. | 4.9 | 91 |
| 35 | Tissue specific distribution of the 3243A->G mtDNA mutation. Journal of Medical Genetics, 2006, 43, 671-677. | 1.5 | 87 |
| 36 | A heterozygous 21-bp deletion inCAPN3causes dominantly inherited limb girdle muscular dystrophy. Brain, 2016, 139, 2154-2163. | 3.7 | 87 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Treatment of Mitochondrial Neurogastrointestinal Encephalomyopathy With Dialysis. Archives of Neurology, 2007, 64, 435. | 4.9 | 86 |
| 38 | COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). Lancet Neurology, The, 2020, 19, 970-971. | 4.9 | 85 |
| 39 | Fuel utilization in subjects with carnitine palmitoyltransferase 2 gene mutations. Annals of Neurology, 2005, 57, 60-66. | 2.8 | 81 |
| 40 | Severe paraspinal muscle involvement in facioscapulohumeral muscular dystrophy. Neurology, 2014, 83, 1178-1183. | 1.5 | 81 |
| 41 | Quantitative Magnetic Resonance Imaging in Limb-Girdle Muscular Dystrophy 2I: A Multinational Cross-Sectional Study. PLoS ONE, 2014, 9, e90377. | 1.1 | 81 |
| 42 | Endurance training: An effective and safe treatment for patients with LGMD2I. Neurology, 2007, 68, 59-61. | 1.5 | 79 |
| 43 | Fat Replacement of Paraspinal Muscles with Aging in Healthy Adults. Medicine and Science in Sports and Exercise, 2017, 49, 595-601. | 0.2 | 78 |
| 44 | Role of 5â€²AMPâ€activated protein kinase in glycogen synthase activity and glucose utilization: insights from patients with McArdle's disease. Journal of Physiology, 2002, 541, 979-989. | 1.3 | 76 |
| 45 | Effect of Oral Sucrose Shortly Before Exercise on Work Capacity in McArdle Disease. Archives of Neurology, 2008, 65, 786-9. | 4.9 | 74 |
| 46 | Lactate production and clearance in exercise. Effects of training. A miniâ€review. Scandinavian Journal of Medicine and Science in Sports, 1998, 8, 127-131. | 1.3 | 73 |
| 47 | Late-onset Pompe disease is prevalent in unclassified limb-girdle muscular dystrophies. Molecular Genetics and Metabolism, 2013, 110, 287-289. | 0.5 | 73 |
| 48 | MRI as outcome measure in facioscapulohumeral muscular dystrophy: 1-year follow-up of 45 patients. Journal of Neurology, 2017, 264, 438-447. | 1.8 | 72 |
| 49 | Multisystem disorder associated with a missense mutation in the mitochondrial cytochromeb gene. Annals of Neurology, 2001, 50, 540-543. | 2.8 | 71 |
| 50 | Oxidative capacity correlates with muscle mutation load in mitochondrial myopathy. Annals of Neurology, 2003, 54, 86-92. | 2.8 | 71 |
| 51 | Muscle Phenotype and Mutation Load in 51 Persons With the 3243A>G Mitochondrial DNA Mutation. Archives of Neurology, 2006, 63, 1701. | 4.9 | 71 |
| 52 | Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults. JAMA Network Open, 2020, 3, e2020836. | 2.8 | 71 |
| 53 | Effect of diet on exercise tolerance in carnitine palmitoyltransferase II deficiency. Neurology, 2003, 61, 559-561. | 1.5 | 69 |
| 54 | Difference in allelic expression of the CLCN1 gene and the possible influence on the myotonia congenita phenotype. European Journal of Human Genetics, 2004, 12, 738-743. | 1.4 | 69 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Limb girdle muscular dystrophies: classification, clinical spectrum and emerging therapies. Current Opinion in Neurology, 2016, 29, 635-641. | 1.8 | 69 |
| 56 | A new mitochondrial tRNA <sup>Met</sup> gene mutation in a patient with dystrophic muscle and exercise intolerance. Neurology, 1998, 50, 1875-1878. | 1.5 | 67 |
| 57 | No spontaneous second wind in muscle phosphofructokinase deficiency. Neurology, 2004, 62, 82-86. | 1.5 | 64 |
| 58 | Anoctamin 5 muscular dystrophy in Denmark: prevalence, genotypes, phenotypes, cardiac findings, and muscle protein expression. Journal of Neurology, 2013, 260, 2084-2093. | 1.8 | 63 |
| 59 | Effect of deficient muscular glycogenolysis on extramuscular fuel production in exercise. Journal of Applied Physiology, 1992, 72, 1773-1779. | 1.2 | 62 |
| 60 | Sequential targeted exome sequencing of 1001 patients affected by unexplained limb-girdle weakness. Genetics in Medicine, 2020, 22, 1478-1488. | 1.1 | 62 |
| 61 | Cardiac Involvement in Patients With Limb-Girdle Muscular Dystrophy Type 2 and Becker Muscular Dystrophy. Archives of Neurology, 2008, 65, 1196-201. | 4.9 | 61 |
| 62 | Reduced levels of skeletal muscle Na <sup>+</sup> K <sup>+</sup> -ATPase in McArdle disease. Neurology, 1998, 50, 37-40. | 1.5 | 60 |
| 63 | LGMD2I presenting with a characteristic Duchenne or Becker muscular dystrophy phenotype. Neurology, 2005, 64, 1635-1637. | 1.5 | 60 |
| 64 | Sympathetic activation in exercise is not dependent on muscle acidosis. Direct evidence from studies in metabolic myopathies.. Journal of Clinical Investigation, 1998, 101, 1654-1660. | 3.9 | 60 |
| 65 | Carbohydrate- and protein-rich diets in McArdle disease: effects on exercise capacity. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 1359-1363. | 0.9 | 59 |
| 66 | Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naÃ¯ve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study. Neuromuscular Disorders, 2019, 29, 167-186. | 0.3 | 59 |
| 67 | Cardiac involvement in myotonic dystrophy: a nationwide cohort study. European Heart Journal, 2014, 35, 2158-2164. | 1.0 | 56 |
| 68 | Diagnosis of Pompe Disease. JAMA Neurology, 2013, 70, 923. | 4.5 | 55 |
| 69 | MRI in sarcoglycanopathies: a large international cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 72-77. | 0.9 | 55 |
| 70 | Fuel utilization in patients with very long-chain acyl-coa dehydrogenase deficiency. Annals of Neurology, 2004, 56, 279-283. | 2.8 | 53 |
| 71 | A forearm exercise screening test for mitochondrial myopathy. Neurology, 2002, 58, 1533-1538. | 1.5 | 52 |
| 72 | Clinical and molecular characterization of limbâ€girdle muscular dystrophy due to LAMA2 mutations. Muscle and Nerve, 2011, 44, 703-709. | 1.0 | 52 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Exercise fuel mobilization in mitochondrial myopathy: A metabolic dilemma. Annals of Neurology, 1996, 40, 655-662. | 2.8 | 51 |
| 74 | Splice mutations preserve myophosphorylase activity that ameliorates the phenotype in McArdle disease. Brain, 2009, 132, 1545-1552. | 3.7 | 51 |
| 75 | Two- and 6-minute walk tests assess walking capability equally in neuromuscular diseases. Neurology, 2016, 86, 442-445. | 1.5 | 51 |
| 76 | Is muscle glycogenolysis impaired in X-linked phosphorylase b kinase deficiency?. Neurology, 2008, 70, 1876-1882. | 1.5 | 50 |
| 77 | Endocrine function in 97 patients with myotonic dystrophy type 1. Journal of Neurology, 2012, 259, 912-920. | 1.8 | 50 |
| 78 | Reduced ceramide synthase 2 activity causes progressive myoclonic epilepsy. Annals of Clinical and Translational Neurology, 2014, 1, 88-98. | 1.7 | 50 |
| 79 | Clinical and genetic spectrum in limb-girdle muscular dystrophy type 2E. Neurology, 2015, 84, 1772-1781. | 1.5 | 50 |
| 80 | Effect of aerobic training in patients with spinal and bulbar muscular atrophy (Kennedy disease). Neurology, 2009, 72, 317-323. | 1.5 | 49 |
| 81 | Calpain 3 is important for muscle regeneration: Evidence from patients with limb girdle muscular dystrophies. BMC Musculoskeletal Disorders, 2012, 13, 43. | 0.8 | 49 |
| 82 | Mutations inCOA3cause isolated complex IV deficiency associated with neuropathy, exercise intolerance, obesity, and short stature. Journal of Medical Genetics, 2015, 52, 203-207. | 1.5 | 49 |
| 83 | The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study. Brain, 2017, 140, 2295-2305. | 3.7 | 49 |
| 84 | A decline in PABPN1 induces progressive muscle weakness in Oculopharyngeal muscle dystrophy and in muscle aging. Aging, 2013, 5, 412-426. | 1.4 | 49 |
| 85 | Fat metabolism during exercise in patients with McArdle disease. Neurology, 2009, 72, 718-724. | 1.5 | 48 |
| 86 | Aerobic training and postexercise protein in facioscapulohumeral muscular dystrophy. Neurology, 2015, 85, 396-403. | 1.5 | 48 |
| 87 | 31P-MRS of skeletal muscle is not a sensitive diagnostic test for mitochondrial myopathy. Journal of Neurology, 2007, 254, 29-37. | 1.8 | 47 |
| 88 | The cytochrome b p.278Y>C mutation causative of a multisystem disorder enhances superoxide production and alters supramolecular interactions of respiratory chain complexes. Human Molecular Genetics, 2013, 22, 2141-2151. | 1.4 | 46 |
| 89 | MYO-MRI diagnostic protocols in genetic myopathies. Neuromuscular Disorders, 2019, 29, 827-841. | 0.3 | 46 |
| 90 | MRI in Neuromuscular Diseases: An Emerging Diagnostic Tool and Biomarker for Prognosis and Efficacy. Annals of Neurology, 2020, 88, 669-681. | 2.8 | 46 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | New patterns of inheritance in mitochondrial disease. Biochemical and Biophysical Research Communications, 2003, 310, 247-251. | 1.0 | 45 |
| 92 | New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy. Brain, 2020, 143, 2696-2708. | 3.7 | 45 |
| 93 | Accuracy of a machine learning muscle MRI-based tool for the diagnosis of muscular dystrophies. Neurology, 2020, 94, e1094-e1102. | 1.5 | 45 |
| 94 | Shortâ€•and longâ€•term effects of endurance training in patients with mitochondrial myopathy. European Journal of Neurology, 2009, 16, 1336-1339. | 1.7 | 44 |
| 95 | High prevalence of cardiac involvement in patients with myotonic dystrophy type 1: A cross-sectional study. International Journal of Cardiology, 2014, 174, 31-36. | 0.8 | 44 |
| 96 | LAMA2â€•related myopathy: Frequency among congenital and limbâ€girdle muscular dystrophies. Muscle and Nerve, 2015, 52, 547-553. | 1.0 | 44 |
| 97 | Axial myopathy: an overlooked feature of muscle diseases. Brain, 2016, 139, 13-22. | 3.7 | 44 |
| 98 | Resistance training in patients with limbâ€girdle and becker muscular dystrophies. Muscle and Nerve, 2013, 47, 163-169. | 1.0 | 43 |
| 99 | Myocardial fibrosis in patients with myotonic dystrophy type 1: a cardiovascular magnetic resonance study. Journal of Cardiovascular Magnetic Resonance, 2014, 16, 59. | 1.6 | 43 |
| 100 | Training improves oxidative capacity, but not function, in spinal muscular atrophy type III. Muscle and Nerve, 2015, 52, 240-244. | 1.0 | 43 |
| 101 | Contractile properties are disrupted in Becker muscular dystrophy, but not in limb girdle type 2I. Annals of Neurology, 2016, 80, 466-471. | 2.8 | 43 |
| 102 | European muscle MRI study in limb girdle muscular dystrophy type R1/2A (LGMDR1/LGMD2A). Journal of Neurology, 2020, 267, 45-56. | 1.8 | 43 |
| 103 | Clinical presentation and mutations in Danish patients with Wilson disease. European Journal of Human Genetics, 2011, 19, 935-941. | 1.4 | 42 |
| 104 | Oral branched-chain amino acids do not improve exercise capacity in McArdle disease. Neurology, 1998, 51, 1456-1459. | 1.5 | 41 |
| 105 | Muscle Phosphoglycerate Mutase Deficiency Revisited. Archives of Neurology, 2009, 66, 394-8. | 4.9 | 40 |
| 106 | Anti-gravity training improves walking capacity and postural balance in patients with muscular dystrophy. Neuromuscular Disorders, 2014, 24, 492-498. | 0.3 | 40 |
| 107 | Exercise tolerance in carnitine palmitoyltransferase II deficiency with IV and oral glucose. Neurology, 2002, 59, 1046-1051. | 1.5 | 39 |
| 108 | Muscle phosphorylase kinase deficiency. Neurology, 2012, 78, 265-268. | 1.5 | 39 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Effect of sildenafil on skeletal and cardiac muscle in <scp>B</scp>ecker muscular dystrophy. Annals of Neurology, 2014, 76, 550-557. | 2.8 | 39 |
| 110 | The exercise metaboreflex is maintained in the absence of muscle acidosis: insights from muscle microdialysis in humans with McArdle's disease. Journal of Physiology, 2001, 537, 641-649. | 1.3 | 38 |
| 111 | Multiple mtDNA deletions with features of MNGIE. Neurology, 2002, 59, 926-929. | 1.5 | 38 |
| 112 | Exercise intolerance in Glycogen Storage Disease Type III: Weakness or energy deficiency?. Molecular Genetics and Metabolism, 2013, 109, 14-20. | 0.5 | 38 |
| 113 | Muscle MRI in a large cohort of patients with oculopharyngeal muscular dystrophy. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 576-585. | 0.9 | 38 |
| 114 | Growth and differentiation factor 15 as a biomarker for mitochondrial myopathy. Mitochondrion, 2020, 50, 35-41. | 1.6 | 38 |
| 115 | Safety and efficacy of omaveloxolone in patients with mitochondrial myopathy. Neurology, 2020, 94, e687-e698. | 1.5 | 38 |
| 116 | Effect of Fuels on Exercise Capacity in Muscle Phosphoglycerate Mutase Deficiency. Archives of Neurology, 2005, 62, 1440. | 4.9 | 37 |
| 117 | Exercise intolerance in mitochondrial myopathy is not related to lactic acidosis. Annals of Neurology, 2001, 49, 672-676. | 2.8 | 36 |
| 118 | Muscle structural changes in mitochondrial myopathy relate to genotype. Journal of Neurology, 2003, 250, 1328-1334. | 1.8 | 36 |
| 119 | Progression of cardiac involvement in patients with limb-girdle type 2 and Becker muscular dystrophies: A 9-year follow-up study. International Journal of Cardiology, 2015, 182, 403-411. | 0.8 | 36 |
| 120 | Cycle ergometry is not a sensitive diagnostic test for mitochondrial myopathy. Journal of Neurology, 2003, 250, 293-299. | 1.8 | 35 |
| 121 | Physical training for McArdle disease. The Cochrane Library, 2011, , CD007931. | 1.5 | 34 |
| 122 | Phenotypes, genotypes, and prevalence of congenital myopathies older than 5 years in Denmark. Neurology: Genetics, 2017, 3, e140. | 0.9 | 34 |
| 123 | Paternal comeback in mitochondrial DNA inheritance. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 1475-1476. | 3.3 | 34 |
| 124 | Decreased insulin action in skeletal muscle from patients with McArdle's disease. American Journal of Physiology - Endocrinology and Metabolism, 2002, 282, E1267-E1275. | 1.8 | 33 |
| 125 | Decrement of compound muscle action potential is related to mutation type in myotonia congenita. Muscle and Nerve, 2003, 27, 449-455. | 1.0 | 33 |
| 126 | Late onset of stroke-like episode associated with a 3256Câ†'T point mutation of mitochondrial DNA. Journal of the Neurological Sciences, 2003, 214, 17-20. | 0.3 | 33 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Relationship between muscle inflammation and fat replacement assessed by MRI in facioscapulohumeral muscular dystrophy. Journal of Neurology, 2019, 266, 1127-1135. | 1.8 | 33 |
| 128 | Endocrine function over time in patients with myotonic dystrophy type 1. European Journal of Neurology, 2015, 22, 116-122. | 1.7 | 32 |
| 129 | Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibodyâ€“Positive Generalized Myasthenia Gravis. Expert Opinion on Investigational Drugs, 2021, 30, 483-493. | 1.9 | 32 |
| 130 | Prevalence of migraine in persons with the 3243A>G mutation in mitochondrial <scp>DNA</scp>. European Journal of Neurology, 2016, 23, 175-181. | 1.7 | 31 |
| 131 | PGM1 deficiency: Substrate use during exercise and effect of treatment with galactose. Neuromuscular Disorders, 2017, 27, 370-376. | 0.3 | 31 |
| 132 | Phenotype and genotype of muscle ryanodine receptor rhabdomyolysis-myalgia syndrome. Acta Neurologica Scandinavica, 2018, 137, 452-461. | 1.0 | 31 |
| 133 | MSTO1 mutations cause mtDNA depletion, manifesting as muscular dystrophy with cerebellar involvement. Acta Neuropathologica, 2019, 138, 1013-1031. | 3.9 | 31 |
| 134 | No evidence for paternal inheritance of mtDNA in patients with sporadic mtDNA mutations. Journal of the Neurological Sciences, 2004, 218, 99-101. | 0.3 | 30 |
| 135 | â€˜Minimal symptom expressionâ€™ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. Journal of Neurology, 2020, 267, 1991-2001. | 1.8 | 30 |
| 136 | Effect of liver glycogen content on glucose production in running rats. Journal of Applied Physiology, 1989, 66, 318-322. | 1.2 | 29 |
| 137 | Muscle phosphoglycerate mutase deficiency with tubular aggregates: Effect of dantrolene. Annals of Neurology, 1999, 46, 274-277. | 2.8 | 29 |
| 138 | Blocked Muscle Fat Oxidation During Exercise in Neutral Lipid Storage Disease. Archives of Neurology, 2012, 69, 530. | 4.9 | 29 |
| 139 | Aerobic training in persons who have recovered from juvenile dermatomyositis. Neuromuscular Disorders, 2013, 23, 962-968. | 0.3 | 29 |
| 140 | Muscle involvement in limb-girdle muscular dystrophy with GMPPB deficiency (LGMD2T). Neurology: Genetics, 2016, 2, e112. | 0.9 | 29 |
| 141 | cDNA analyses of CAPN3 enhance mutation detection and reveal a low prevalence of LGMD2A patients in Denmark. European Journal of Human Genetics, 2008, 16, 935-940. | 1.4 | 28 |
| 142 | Change in muscle strength over time in spinal muscular atrophy types II and III. A long-term follow-up study. Neuromuscular Disorders, 2012, 22, 1069-1074. | 0.3 | 28 |
| 143 | Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial. Lancet Neurology, The, 2018, 17, 1043-1052. | 4.9 | 28 |
| 144 | Natural history of limb girdle muscular dystrophy R9 over 6Âyears: searching for trial endpoints. Annals of Clinical and Translational Neurology, 2019, 6, 1033-1045. | 1.7 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Recurrent TTN metatranscriptâ€only c.39974â€“11T>G splice variant associated with autosomal recessive arthrogryposis multiplex congenita and myopathy. Human Mutation, 2020, 41, 403-411. | 1.1 | 28 |
| 146 | Fat and carbohydrate metabolism during exercise in late-onset Pompe disease. Molecular Genetics and Metabolism, 2012, 107, 462-468. | 0.5 | 27 |
| 147 | <scp>EFNS</scp> review on the role of muscle biopsy in the investigation of myalgia. European Journal of Neurology, 2013, 20, 997-1005. | 1.7 | 27 |
| 148 | Pharmacologic Treatment of Downstream of Tyrosine Kinase 7 Congenital Myasthenic Syndrome. JAMA Neurology, 2014, 71, 350. | 4.5 | 27 |
| 149 | Fatigue in patients with spinal muscular atrophy type II and congenital myopathies: evaluation of the fatigue severity scale. Quality of Life Research, 2014, 23, 1479-1488. | 1.5 | 27 |
| 150 | Exercise in muscle glycogen storage diseases. Journal of Inherited Metabolic Disease, 2015, 38, 551-563. | 1.7 | 27 |
| 151 | Resistance training and aerobic training improve muscle strength and aerobic capacity in chronic inflammatory demyelinating polyneuropathy. Muscle and Nerve, 2018, 57, 70-76. | 1.0 | 27 |
| 152 | POPDC3 Gene Variants Associate with a New Form of Limb Girdle Muscular Dystrophy. Annals of Neurology, 2019, 86, 832-843. | 2.8 | 27 |
| 153 | Evaluation of inflammatory lesions over 2 years in facioscapulohumeral muscular dystrophy. Neurology, 2020, 95, e1211-e1221. | 1.5 | 27 |
| 154 | Nampt controls skeletal muscle development by maintaining Ca2+ homeostasis and mitochondrial integrity. Molecular Metabolism, 2021, 53, 101271. | 3.0 | 27 |
| 155 | Effect of Changes in Fat Availability on Exercise Capacity in McArdle Disease. Archives of Neurology, 2009, 66, 762-6. | 4.9 | 26 |
| 156 | Level of muscle regeneration in limb-girdle muscular dystrophy type 2I relates to genotype and clinical severity. Skeletal Muscle, 2011, 1, 31. | 1.9 | 26 |
| 157 | Fat and Carbohydrate Metabolism During Exercise in Phosphoglucomutase Type 1 Deficiency. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1235-E1240. | 1.8 | 26 |
| 158 | Skeletal muscle metabolism is impaired during exercise in glycogen storage disease type III. Neurology, 2015, 84, 1767-1771. | 1.5 | 26 |
| 159 | No effect of bezafibrate in patients with CPTII and VLCAD deficiencies. Journal of Inherited Metabolic Disease, 2015, 38, 373-374. | 1.7 | 26 |
| 160 | High-intensity interval training in facioscapulohumeral muscular dystrophy type 1: a randomized clinical trial. Journal of Neurology, 2017, 264, 1099-1106. | 1.8 | 26 |
| 161 | Disease progression and outcome measures in spinobulbar muscular atrophy. Annals of Neurology, 2018, 84, 754-765. | 2.8 | 25 |
| 162 | Impairments in contractility and cytoskeletal organisation cause nuclear defects in nemaline myopathy. Acta Neuropathologica, 2019, 138, 477-495. | 3.9 | 25 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Patients With Medium-Chain Acylâ€“Coenzyme A Dehydrogenase Deficiency Have Impaired Oxidation of Fat During Exercise but No Effect of<scp>l</scp>-Carnitine Supplementation. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1667-1675. | 1.8 | 24 |
| 164 | Differential Muscle Involvement in Mice and Humans Affected by McArdle Disease. Journal of Neuropathology and Experimental Neurology, 2016, 75, 441-454. | 0.9 | 24 |
| 165 | Decreased Variability of the 6-Minute Walk Test by Heart Rate Correction in Patients with Neuromuscular Disease. PLoS ONE, 2014, 9, e114273. | 1.1 | 24 |
| 166 | Do carriers of PYGM mutations have symptoms of McArdle disease?. Neurology, 2006, 67, 716-718. | 1.5 | 23 |
| 167 | Lactate metabolism during exercise in patients with mitochondrial myopathy. Neuromuscular Disorders, 2013, 23, 629-636. | 0.3 | 23 |
| 168 | Creatine kinase response to highâ€intensity aerobic exercise in adultâ€onset muscular dystrophy. Muscle and Nerve, 2013, 48, 897-901. | 1.0 | 23 |
| 169 | Ocular, bulbar, limb, and cardiopulmonary involvement in oculopharyngeal muscular dystrophy. Acta Neurologica Scandinavica, 2014, 130, 125-130. | 1.0 | 23 |
| 170 | Update on new muscle glycogenosis. Current Opinion in Neurology, 2017, 30, 449-456. | 1.8 | 23 |
| 171 | Refining the spinobulbar muscular atrophy phenotype by quantitative MRI and clinical assessments. Neurology, 2019, 92, e548-e559. | 1.5 | 23 |
| 172 | Data from the European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC). Orphanet Journal of Rare Diseases, 2020, 15, 330. | 1.2 | 23 |
| 173 | Paradoxically enhanced glucose production during exercise in humans with blocked glycolysis caused by muscle phosphofructokinase deficiency. Neurology, 1996, 47, 766-771. | 1.5 | 22 |
| 174 | Recurrent myoglobinuria and deranged acylcarnitines due to a mutation in the mtDNA MT-CO2 gene. Neurology, 2013, 80, 1908-1910. | 1.5 | 22 |
| 175 | Muscle Atrophy Reversed by Growth Factor Activation of Satellite Cells in a Mouse Muscle Atrophy Model. PLoS ONE, 2014, 9, e100594. | 1.1 | 22 |
| 176 | Intact transferrin and total plasma glycoprofiling for diagnosis and therapy monitoring in phosphoglucomutase-I deficiency. Translational Research, 2018, 199, 62-76. | 2.2 | 22 |
| 177 | Aerobic training in patients with anoctamin 5 myopathy and hyperckemia. Muscle and Nerve, 2014, 50, 119-123. | 1.0 | 21 |
| 178 | Reliability of the 2- and 6-minute walk tests in neuromuscular diseases. Journal of Rehabilitation Medicine, 2017, 49, 362-366. | 0.8 | 21 |
| 179 | Characterization of two new dominant ClC-1 channel mutations associated with myotonia. Muscle and Nerve, 2003, 28, 722-732. | 1.0 | 20 |
| 180 | Limited diagnostic value of enzyme analysis in patients with mitochondrial tRNA mutations. Muscle and Nerve, 2010, 41, 607-613. | 1.0 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Muscle strength in myasthenia gravis. Acta Neurologica Scandinavica, 2014, 129, 367-373. | 1.0 | 20 |
| 182 | Exercise Therapy in Spinobulbar Muscular Atrophy and Other Neuromuscular Disorders. Journal of Molecular Neuroscience, 2016, 58, 388-393. | 1.1 | 20 |
| 183 | Adaptations in Mitochondrial Enzymatic Activity Occurs Independent of Genomic Dosage in Response to Aerobic Exercise Training and Deconditioning in Human Skeletal Muscle. Cells, 2019, 8, 237. | 1.8 | 20 |
| 184 | Genetic analysis of Charcot-Marie-Tooth disease in Denmark and the implementation of a next generation sequencing platform. European Journal of Medical Genetics, 2019, 62, 1-8. | 0.7 | 20 |
| 185 | Titrating a modified ketogenic diet for patients with McArdle disease: A pilot study. Journal of Inherited Metabolic Disease, 2020, 43, 778-786. | 1.7 | 20 |
| 186 | Global FKRP Registry: observations in more than 300 patients with Limb Girdle Muscular Dystrophy R9. Annals of Clinical and Translational Neurology, 2020, 7, 757-766. | 1.7 | 20 |
| 187 | Impaired glycogen breakdown and synthesis in phosphoglucomutase 1 deficiency. Molecular Genetics and Metabolism, 2017, 122, 117-121. | 0.5 | 19 |
| 188 | Antimyostatin Treatment in Health and Disease: The Story of Great Expectations and Limited Success. Cells, 2021, 10, 533. | 1.8 | 19 |
| 189 | Regulation of hepatic glucose production in running rats studied by glucose infusion. Journal of Applied Physiology, 1988, 65, 2552-2557. | 1.2 | 18 |
| 190 | EFFECTS OF IV GLUCOSE AND ORAL MEDIUM-CHAIN TRIGLYCERIDE IN PATIENTS WITH VLCAD DEFICIENCY. Neurology, 2007, 69, 313-315. | 1.5 | 18 |
| 191 | High Prevalence of Impaired Glucose Homeostasis and Myopathy in Asymptomatic and Oligosymptomatic 3243A>G Mitochondrial DNA Mutation-Positive Subjects. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2872-2879. | 1.8 | 18 |
| 192 | Severe Axial Myopathy in McArdle Disease. JAMA Neurology, 2014, 71, 88. | 4.5 | 18 |
| 193 | A New Mouse Model of Limb-Girdle Muscular Dystrophy Type 2I Homozygous for the Common L276I Mutation Mimicking the Mild Phenotype in Humans. Journal of Neuropathology and Experimental Neurology, 2015, 74, 1137-1146. | 0.9 | 18 |
| 194 | Prevalence and phenotypes of congenital myopathy due to Î±â€actin 1 gene mutations. Muscle and Nerve, 2016, 53, 388-393. | 1.0 | 18 |
| 195 | Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study. Journal of the Neurological Sciences, 2019, 407, 116419. | 0.3 | 18 |
| 196 | Ventromedial hypothalamic regulation of hormonal and metabolic responses to exercise. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1989, 256, R1019-R1026. | 0.9 | 17 |
| 197 | No muscle involvement in myoclonusâ€dystonia caused by Ɛâ€sarcoglycan gene mutations. European Journal of Neurology, 2008, 15, 525-529. | 1.7 | 17 |
| 198 | Sequence variants in SPAST, SPG3A and HSPD1 in hereditary spastic paraplegia. Journal of the Neurological Sciences, 2009, 284, 90-95. | 0.3 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Fat Metabolism During Exercise in Patients With Mitochondrial Disease. Archives of Neurology, 2009, 66, 365-70. | 4.9 | 17 |
| 200 | Effect of enzyme replacement therapy on isokinetic strength for all major muscle groups in four patients with Pompe diseaseâ€"a long-term follow-up. Molecular Genetics and Metabolism, 2014, 112, 40-43. | 0.5 | 17 |
| 201 | Frequency and phenotype of patients carrying TPM2 and TPM3 gene mutations in a cohort of 94 patients with congenital myopathy. Neuromuscular Disorders, 2014, 24, 325-330. | 0.3 | 17 |
| 202 | Mitochondrial dysfunction and risk of cancer. British Journal of Cancer, 2015, 112, 1134-1140. | 2.9 | 17 |
| 203 | Aerobic Training in Patients with Congenital Myopathy. PLoS ONE, 2016, 11, e0146036. | 1.1 | 17 |
| 204 | No effect of triheptanoin on exercise performance in McArdle disease. Annals of Clinical and Translational Neurology, 2019, 6, 1949-1960. | 1.7 | 17 |
| 205 | Deep morphological analysis of muscle biopsies from type III glycogenesis (GSDIII), debranching enzyme deficiency, revealed stereotyped vacuolar myopathy and autophagy impairment. Acta Neuropathologica Communications, 2019, 7, 167. | 2.4 | 17 |
| 206 | Muscle contractility in spinobulbar muscular atrophy. Scientific Reports, 2019, 9, 4680. | 1.6 | 17 |
| 207 | Permanent muscle weakness in hypokalemic periodic paralysis. Neurology, 2020, 95, e342-e352. | 1.5 | 17 |
| 208 | Impaired energy metabolism and abnormal muscle histology in mut- methylmalonic aciduria. Neurology, 2005, 65, 931-933. | 1.5 | 16 |
| 209 | Mechanisms of exertional fatigue in muscle glycogenoses. Neuromuscular Disorders, 2012, 22, S168-S171. | 0.3 | 16 |
| 210 | SCA28: Novel Mutation in the AFG3L2 Proteolytic Domain Causes a Mild Cerebellar Syndrome with Selective Type-1 Muscle Fiber Atrophy. Cerebellum, 2017, 16, 62-67. | 1.4 | 16 |
| 211 | Glycogen Synthesis in Glycogenin 1â€"Deficient Patients: A Role for Glycogenin 2 in Muscle. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2690-2700. | 1.8 | 16 |
| 212 | Deep phenotyping of facioscapulohumeral muscular dystrophy type 2 by magnetic resonance imaging. European Journal of Neurology, 2020, 27, 2604-2615. | 1.7 | 16 |
| 213 | Consistent improvement with eculizumab across muscle groups in myasthenia gravis. Annals of Clinical and Translational Neurology, 2020, 7, 1327-1339. | 1.7 | 16 |
| 214 | Effect of Aerobic Exercise Training and Deconditioning on Oxidative Capacity and Muscle Mitochondrial Enzyme Machinery in Young and Elderly Individuals. Journal of Clinical Medicine, 2020, 9, 3113. | 1.0 | 16 |
| 215 | Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease. Neurology, 2022, 99, . | 1.5 | 16 |
| 216 | Becker muscular dystrophy with widespread muscle hypertrophy and a non-sense mutation of exon 2. Neuromuscular Disorders, 2013, 23, 25-28. | 0.3 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Muscle regeneration and inflammation in patients with facioscapulohumeral muscular dystrophy. Acta Neurologica Scandinavica, 2013, 128, 194-201. | 1.0 | 15 |
| 218 | A pilot study of muscle plasma protein changes after exercise. Muscle and Nerve, 2014, 49, 261-266. | 1.0 | 15 |
| 219 | Protein-carbohydrate supplements improve muscle protein balance in muscular dystrophy patients after endurance exercise: a placebo-controlled crossover study. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2015, 308, R123-R130. | 0.9 | 15 |
| 220 | L-Carnitine Improves Skeletal Muscle Fat Oxidation in Primary Carnitine Deficiency. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4580-4588. | 1.8 | 15 |
| 221 | Level of residual enzyme activity modulates the phenotype in phosphoglycerate kinase deficiency. Neurology, 2018, 91, e1077-e1082. | 1.5 | 15 |
| 222 | A single c.1715G>C calpain 3 gene variant causes dominant calpainopathy with loss of calpain 3 expression and activity. Human Mutation, 2020, 41, 1507-1513. | 1.1 | 15 |
| 223 | Treatment Opportunities in Patients With Metabolic Myopathies. Current Treatment Options in Neurology, 2017, 19, 37. | 0.7 | 14 |
| 224 | Effects of Sildenafil on Cerebrovascular Reactivity in Patients with Becker Muscular Dystrophy. Neurotherapeutics, 2017, 14, 182-190. | 2.1 | 14 |
| 225 | High-intensity training in patients with spinal and bulbar muscular atrophy. Journal of Neurology, 2019, 266, 1693-1697. | 1.8 | 14 |
| 226 | 249th ENMC International Workshop: The role of brain dystrophin in muscular dystrophy: Implications for clinical care and translational research, Hoofddorp, The Netherlands, November 29thâ€“December 1st 2019. Neuromuscular Disorders, 2020, 30, 782-794. | 0.3 | 14 |
| 227 | Phenotype and clinical course in a family with a new de novo Twinkle gene mutation. Neuromuscular Disorders, 2008, 18, 306-309. | 0.3 | 13 |
| 228 | Muscle phenotype in patients with myotonic dystrophy type 1. Muscle and Nerve, 2013, 47, 409-415. | 1.0 | 13 |
| 229 | Insulin Resistance and Increased Muscle Cytokine Levels in Patients With Mitochondrial Myopathy. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3757-3765. | 1.8 | 13 |
| 230 | A novel de novo mutation of the mitochondrial tRNAlys gene mt.8340G>A associated with pure myopathy. Neuromuscular Disorders, 2014, 24, 162-166. | 0.3 | 13 |
| 231 | Muscle imaging in patients with tubular aggregate myopathy caused by mutations in STIM1. Neuromuscular Disorders, 2015, 25, 898-903. | 0.3 | 13 |
| 232 | Body weight-supported training in Becker and limb girdle 2I muscular dystrophy. Muscle and Nerve, 2016, 54, 239-243. | 1.0 | 13 |
| 233 | Muscle glycogen synthesis and breakdown are both impaired in glycogenin-1 deficiency. Neurology, 2017, 89, 2491-2494. | 1.5 | 13 |
| 234 | Aberrant regulation of epigenetic modifiers contributes to the pathogenesis in patients with selenoprotein N â€ related myopathies. Human Mutation, 2019, 40, 962-974. | 1.1 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Preclinical Research in Glycogen Storage Diseases: A Comprehensive Review of Current Animal Models. International Journal of Molecular Sciences, 2020, 21, 9621. | 1.8 | 13 |
| 236 | Muscle involvement assessed by quantitative magnetic resonance imaging in patients with anoctamin 5 deficiency. European Journal of Neurology, 2021, 28, 3121-3132. | 1.7 | 13 |
| 237 | Fatigue, physical activity and associated factors in 779 patients with myasthenia gravis. Neuromuscular Disorders, 2021, 31, 716-725. | 0.3 | 13 |
| 238 | Lack of IL-6 production during exercise in patients with mitochondrial myopathy. European Journal of Applied Physiology, 2001, 84, 155-157. | 1.2 | 12 |
| 239 | Myopathic EMG findings and type II muscle fiber atrophy in patients with Lambert-Eaton myasthenic syndrome. Clinical Neurophysiology, 2013, 124, 1889-1892. | 0.7 | 12 |
| 240 | Risk of cancer in relatives of patients with myotonic dystrophy: a populationâ€based cohort study. European Journal of Neurology, 2014, 21, 1192-1197. | 1.7 | 12 |
| 241 | Hydroxylated long-chain acylcarnitines are biomarkers of mitochondrial myopathy. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5968-5976. | 1.8 | 12 |
| 242 | Exercise training in metabolic myopathies. Revue Neurologique, 2016, 172, 559-565. | 0.6 | 11 |
| 243 | Differential glucose metabolism in mice and humans affected by McArdle disease. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2016, 311, R307-R314. | 0.9 | 11 |
| 244 | Collagen XII myopathy with rectus femoris atrophy and collagen XII retention in fibroblasts. Muscle and Nerve, 2018, 57, 1026-1030. | 1.0 | 11 |
| 245 | Lecocytes mutation load declines with age in carriers of the m.3243A>G mutation: A 10â€year Prospective Cohort. Clinical Genetics, 2018, 93, 925-928. | 1.0 | 11 |
| 246 | BAG3 myopathy is not always associated with cardiomyopathy. Neuromuscular Disorders, 2018, 28, 798-801. | 0.3 | 11 |
| 247 | Low survival rate and muscle fiber-dependent aging effects in the McArdle disease mouse model. Scientific Reports, 2019, 9, 5116. | 1.6 | 11 |
| 248 | Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of <scp>REGAIN</scp> and its extension study. Muscle and Nerve, 2021, 64, 662-669. | 1.0 | 11 |
| 249 | No effect of oral ketone ester supplementation on exercise capacity in patients with <scp>McArdle</scp> disease and healthy controls: A randomized placeboâ€controlled crossâ€over study. Journal of Inherited Metabolic Disease, 2022, 45, 502-516. | 1.7 | 11 |
| 250 | Exercise intolerance in mitochondrial myopathy is not related to lactic acidosis. Annals of Neurology, 2001, 49, 672-6. | 2.8 | 11 |
| 251 | Frequency and Phenotype of Myotubular Myopathy Amongst Danish Patients with Congenital Myopathy Older than 5 Years. Journal of Neuromuscular Diseases, 2015, 2, 167-174. | 1.1 | 10 |
| 252 | Lactate and Energy Metabolism During Exercise in Patients With Blocked Glycogenolysis (McArdle) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 | 1.8 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Towards a European Registry and Biorepository for Patients with Spinal and Bulbar Muscular Atrophy. Journal of Molecular Neuroscience, 2016, 58, 394-400. | 1.1 | 10 |
| 254 | Congenital myopathies are mainly associated with a mild cardiac phenotype. Journal of Neurology, 2019, 266, 1367-1375. | 1.8 | 10 |
| 255 | Preserved Capacity for Adaptations in Strength and Muscle Regulatory Factors in Elderly in Response to Resistance Exercise Training and Deconditioning. Journal of Clinical Medicine, 2020, 9, 2188. | 1.0 | 10 |
| 256 | Stable Longitudinal Methylation Levels at the CpG Sites Flanking the CTG Repeat of DMPK in Patients with Myotonic Dystrophy Type 1. Genes, 2020, 11, 936. | 1.0 | 10 |
| 257 | Characteristic muscle signatures assessed by quantitative MRI in patients with Bethlem myopathy. Journal of Neurology, 2020, 267, 2432-2442. | 1.8 | 10 |
| 258 | Impaired lipolysis in propionic acidemia: A new metabolic myopathy?. JIMD Reports, 2020, 53, 16-21. | 0.7 | 10 |
| 259 | Visual impairment in anti-GQ1b positive Miller Fisher syndrome. Acta Neurologica Scandinavica, 2001, 103, 259-60. | 1.0 | 10 |
| 260 | High Resolution Analysis of DMPK Hypermethylation and Repeat Interruptions in Myotonic Dystrophy Type 1. Genes, 2022, 13, 970. | 1.0 | 10 |
| 261 | Visual impairment in anti-GQ1b positive Miller Fisher syndrome. Acta Neurologica Scandinavica, 2001, 103, 259-260. | 1.0 | 9 |
| 262 | Effect of Gender, Disease Duration and Treatment on Muscle Strength in Myasthenia Gravis. PLoS ONE, 2016, 11, e0164092. | 1.1 | 9 |
| 263 | 1st International Workshop on Clinical trial readiness for sarcoglycanopathies 15â€“16 November 2016, Evry, France. Neuromuscular Disorders, 2017, 27, 683-692. | 0.3 | 9 |
| 264 | Mitochondrial Point Mutation m.3243A>G Associates With Lower Bone Mineral Density, Thinner Cortices, and Reduced Bone Strength: A Case-Control Study. Journal of Bone and Mineral Research, 2017, 32, 2041-2048. | 3.1 | 9 |
| 265 | Dysphagia is prevalent in patients with CPEO and single, large-scale deletions in mtDNA. Mitochondrion, 2017, 32, 27-30. | 1.6 | 9 |
| 266 | Screening for late-onset Pompe disease in western Denmark. Acta Neurologica Scandinavica, 2018, 137, 85-90. | 1.0 | 9 |
| 267 | Homozygosity for SCN4A Arg1142Gln causes congenital myopathy with variable disease expression. Neurology: Genetics, 2018, 4, e267. | 0.9 | 9 |
| 268 | Depletion of ATP Limits Membrane Excitability of Skeletal Muscle by Increasing Both ClC1-Open Probability and Membrane Conductance. Frontiers in Neurology, 2020, 11, 541. | 1.1 | 9 |
| 269 | Quantitative Muscle MRI as Outcome Measure in Patients With Becker Muscular Dystrophyâ€”A 1-Year Follow-Up Study. Frontiers in Neurology, 2020, 11, 613489. | 1.1 | 9 |
| 270 | Improving Care and Empowering Adults Living with SMA: A Call to Action in the New Treatment Era. Journal of Neuromuscular Diseases, 2021, 8, 543-551. | 1.1 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 271 | 1st FSHD European Trial Network workshop:Working towards trial readiness across Europe. Neuromuscular Disorders, 2021, 31, 907-918. | 0.3 | 9 |
| 272 | Quantitative Muscle MRI and Clinical Findings in Women With Pathogenic Dystrophin Gene Variants. Frontiers in Neurology, 2021, 12, 707837. | 1.1 | 9 |
| 273 | Diagnostic challenges in combined multiple sclerosis and centronuclear myopathy. European Journal of Neurology, 2000, 7, 567-571. | 1.7 | 8 |
| 274 | Influence of erythrocyte oxygenation and intravascular ATP on resting and exercising skeletal muscle blood flow in humans with mitochondrial myopathy. Mitochondrion, 2012, 12, 414-422. | 1.6 | 8 |
| 275 | A mitochondrial tRNAMet mutation causing developmental delay, exercise intolerance and limb girdle phenotype with onset in early childhood. European Journal of Paediatric Neurology, 2015, 19, 69-71. | 0.7 | 8 |
| 276 | Skeletal muscle metabolism during prolonged exercise in Pompe disease. Endocrine Connections, 2017, 6, 384-394. | 0.8 | 8 |
| 277 | Progressive fat replacement of muscle contributes to the disease mechanism of patients with single, large-scale deletions of mitochondrial DNA. Neuromuscular Disorders, 2018, 28, 408-413. | 0.3 | 8 |
| 278 | Expanding the phenotype of filamin-C-related myofibrillar myopathy. Clinical Neurology and Neurosurgery, 2019, 176, 30-33. | 0.6 | 8 |
| 279 | A quantitative method to assess muscle edema using short TI inversion recovery MRI. Scientific Reports, 2020, 10, 7246. | 1.6 | 8 |
| 280 | Exercise Testing, Physical Training and Fatigue in Patients with Mitochondrial Myopathy Related to mtDNA Mutations. Journal of Clinical Medicine, 2021, 10, 1796. | 1.0 | 8 |
| 281 | Cardiac Involvement in Women With Pathogenic Dystrophin Gene Variants. Frontiers in Neurology, 2021, 12, 707838. | 1.1 | 8 |
| 282 | Exercise therapy for muscle and lower motor neuron diseases. Acta Myologica, 2019, 38, 215-232. | 1.5 | 8 |
| 283 | Highâ€resolution Melting Facilitates Mutation Screening of PYGM in Patients with McArdle Disease. Annals of Human Genetics, 2009, 73, 292-297. | 0.3 | 7 |
| 284 | LGMD2L with bone affection: Overlapping phenotype of dominant and recessive ANO5â€induced disease. Muscle and Nerve, 2012, 46, 829-830. | 1.0 | 7 |
| 285 | A new mutation of the fukutin gene causing late-onset limb girdle muscular dystrophy. Neuromuscular Disorders, 2013, 23, 562-567. | 0.3 | 7 |
| 286 | Protein Turnover and Cellular Stress in Mildly and Severely Affected Muscles from Patients with Limb Girdle Muscular Dystrophy Type 2I. PLoS ONE, 2013, 8, e66929. | 1.1 | 7 |
| 287 | Muscle Strength and Aerobic Capacity in Patients with CIDP One Year after Participation in an Exercise Trial. Journal of Neuromuscular Diseases, 2019, 6, 93-97. | 1.1 | 7 |
| 288 | Mutation Load of Single, Large-Scale Deletions of mtDNA in Mitotic and Postmitotic Tissues. Frontiers in Genetics, 2020, 11, 547638. | 1.1 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 289 | Intrarater reliability and validity of outcome measures in myotonic dystrophy type 1. Neurology, 2020, 94, e2508-e2520. | 1.5 | 7 |
| 290 | Physical activity in myotonic dystrophy type 1. Journal of Neurology, 2020, 267, 1679-1686. | 1.8 | 7 |
| 291 | No effect of resveratrol on fatty acid oxidation or exercise capacity in patients with fatty acid oxidation disorders: A randomized clinical crossâ€over trial. Journal of Inherited Metabolic Disease, 2022, 45, 517-528. | 1.7 | 7 |
| 292 | Effect of anaesthetizing the region of the paraventricular hypothalamic nuclei on energy metabolism during exercise in the rat. Acta Physiologica Scandinavica, 1994, 151, 165-172. | 2.3 | 6 |
| 293 | Against a role of lactic acid on the generation of the exercise pressor reflex. Clinical Autonomic Research, 2003, 13, 83-84. | 1.4 | 6 |
| 294 | Drilling for Energy in Mitochondrial Disease. Archives of Neurology, 2009, 66, 931-2. | 4.9 | 6 |
| 295 | Muscle regeneration in mitochondrial myopathies. Mitochondrion, 2013, 13, 63-70. | 1.6 | 6 |
| 296 | Human growth hormone stabilizes walking and improves strength in a patient with dominantly inherited calpainopathy. Neuromuscular Disorders, 2017, 27, 358-362. | 0.3 | 6 |
| 297 | Leber hereditary optic neuropathy due to a new ND1 mutation. Ophthalmic Genetics, 2017, 38, 480-485. | 0.5 | 6 |
| 298 | 211th ENMC International Workshop:. Neuromuscular Disorders, 2017, 27, 1143-1151. | 0.3 | 6 |
| 299 | Reply: Dominant LGMD2A: alternative diagnosis or hidden digenism?. Brain, 2017, 140, e8-e8. | 3.7 | 6 |
| 300 | Pure exercise intolerance and ophthalmoplegia associated with the m.12,294GÂ>ÂA mutation in the MT-TL2 gene: a case report. BMC Musculoskeletal Disorders, 2017, 18, 419. | 0.8 | 6 |
| 301 | Fat oxidation is impaired during exercise in lipin-1 deficiency. Neurology, 2019, 93, e1433-e1438. | 1.5 | 6 |
| 302 | Muscle biopsy and <scp>MRI</scp> findings in <scp>ANO5</scp>â€related myopathy. Muscle and Nerve, 2021, 64, 743-748. | 1.0 | 6 |
| 303 | Causes of symptom dissatisfaction in patients with generalized myasthenia gravis. Journal of Neurology, 2022, 269, 3086-3093. | 1.8 | 6 |
| 304 | Muscle phosphoglycerate mutase deficiency with tubular aggregates: effect of dantrolene. Annals of Neurology, 1999, 46, 274-7. | 2.8 | 6 |
| 305 | Muscle reflex and central motor control of neuroendocrine activity, glucose homeostasis and circulation during exercise. Acta Physiologica Scandinavica Supplementum, 2000, 647, 1-26. | 1.0 | 6 |
| 306 | Botulinum toxin treatment improves dysphagia in patients with oculopharyngeal muscular dystrophy and sporadic inclusion body myositis. Journal of Neurology, 2022, 269, 4154-4160. | 1.8 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 307 | Effect of prior immobilization on muscular glucose clearance in resting and running rats. American Journal of Physiology - Endocrinology and Metabolism, 1988, 255, E456-E462. | 1.8 | 5 |
| 308 | Clinical and neurophysiological response to pharmacological treatment of DOK7 congenital myasthenia in an older patient. Clinical Neurology and Neurosurgery, 2015, 130, 168-170. | 0.6 | 5 |
| 309 | Aerobic antiâ€gravity exercise in patients with Charcotâ€“Marieâ€“Tooth disease types 1A and X: A pilot study. Brain and Behavior, 2017, 7, e00794. | 1.0 | 5 |
| 310 | Correlation between myasthenia gravisâ^'activities of daily living (MGâ€ADL) and quantitative myasthenia gravis (QMG) assessments of antiâ^'acetylcholine receptor antibodyâ^'positive refractory generalized myasthenia gravis in the phase 3 regain study. Muscle and Nerve, 2018, 58, E21-E22. | 1.0 | 5 |
| 311 | 233rd ENMC International Workshop:. Neuromuscular Disorders, 2018, 28, 540-549. | 0.3 | 5 |
| 312 | Exercising with blocked muscle glycogenolysis: Adaptation in the McArdle mouse. Molecular Genetics and Metabolism, 2018, 123, 21-27. | 0.5 | 5 |
| 313 | Muscle contractility of leg muscles in patients with mitochondrial myopathies. Mitochondrion, 2019, 46, 221-227. | 1.6 | 5 |
| 314 | A New Glycogen Storage Disease Caused by a DominantPYGMMutation. Annals of Neurology, 2020, 88, 274-282. | 2.8 | 5 |
| 315 | Episodic hyperCKaemia may be a feature of Î±â€methylacylâ€coenzyme A racemase deficiency. European Journal of Neurology, 2021, 28, 729-731. | 1.7 | 5 |
| 316 | Diagnostic interest of whole-body MRI in early- and late-onset LAMA2 muscular dystrophies: a large international cohort. Journal of Neurology, 2022, 269, 2414-2429. | 1.8 | 5 |
| 317 | Phenotypic Spectrum of Î±-Dystroglycanopathies Associated With the c.919T>a Variant in the FKRP Gene in Humans and Mice. Journal of Neuropathology and Experimental Neurology, 2020, 79, 1257-1264. | 0.9 | 5 |
| 318 | Deletion of exon 26 of the dystrophin gene is associated with a mild Becker muscular dystrophy phenotype. Acta Myologica, 2011, 30, 182-4. | 1.5 | 5 |
| 319 | O.22 Dominant inheritance of limb girdle muscular dystrophy type 2A. Neuromuscular Disorders, 2011, 21, 750. | 0.3 | 4 |
| 320 | Exercise Intolerance and Myoglobinuria Associated with a Novel Maternally Inherited MT-ND1 Mutation. JIMD Reports, 2015, 25, 65-70. | 0.7 | 4 |
| 321 | Moderateâ€intensity aerobic exercise improves physical fitness in bethlem myopathy. Muscle and Nerve, 2019, 60, 183-188. | 1.0 | 4 |
| 322 | Absence of p.R50X Pygm read-through in McArdle disease cellular models. DMM Disease Models and Mechanisms, 2019, 13, . | 1.2 | 4 |
| 323 | No effect of oral sucrose or IV glucose during exercise in phosphorylase b kinase deficiency. Neuromuscular Disorders, 2020, 30, 340-345. | 0.3 | 4 |
| 324 | 251st ENMC international workshop: Polyglucosan storage myopathies 13â€“15 December 2019, Hoofddorp, the Netherlands. Neuromuscular Disorders, 2021, 31, 466-477. | 0.3 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 325 | No effect of resveratrol in patients with mitochondrial myopathy: A crossâ€over randomized controlled trial. Journal of Inherited Metabolic Disease, 2021, 44, 1186-1198. | 1.7 | 4 |
| 326 | Habitual Physical Activity in Patients with Myasthenia Gravis Assessed by Accelerometry and Questionnaire. Journal of Neuromuscular Diseases, 2022, 9, 161-169. | 1.1 | 4 |
| 327 | Prolonged fastingâ€induced hyperketosis, hypoglycaemia and impaired fat oxidation in child and adult patients with spinal muscular atrophy type II. Acta Paediatrica, International Journal of Paediatrics, 2021, 110, 3367-3375. | 0.7 | 4 |
| 328 | Mitochondrial mutation m.3243A>G associates with insulin resistance in non-diabetic carriers. Endocrine Connections, 2019, 8, 829-837. | 0.8 | 4 |
| 329 | Preclinical Research in McArdle Disease: A Review of Research Models and Therapeutic Strategies. Genes, 2022, 13, 74. | 1.0 | 4 |
| 330 | Role of metabolic feedback regulation in glucose production of running rats. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1988, 255, R400-R406. | 0.9 | 3 |
| 331 | Myositis in Griscelli syndrome type 2 treated with hematopoietic cell transplantation. Neuromuscular Disorders, 2010, 20, 136-138. | 0.3 | 3 |
| 332 | Cytokine genes as potential biomarkers for muscle weakness in OPMD. Human Molecular Genetics, 2016, 25, 4282-4287. | 1.4 | 3 |
| 333 | DOK7 congenital myasthenia may be associated with severe mitral valve insufficiency. Journal of the Neurological Sciences, 2017, 379, 217-218. | 0.3 | 3 |
| 334 | Aerobic training in myotonia congenita: Effect on myotonia and fitness. Muscle and Nerve, 2017, 56, 696-699. | 1.0 | 3 |
| 335 | Mitochondrial <scp>DNA</scp> mutation load in a family with the m.8344A>G point mutation and lipomas: a case study. Clinical Case Reports (discontinued), 2017, 5, 2034-2039. | 0.2 | 3 |
| 336 | Creation and implementation of a European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC registry). Orphanet Journal of Rare Diseases, 2020, 15, 187. | 1.2 | 3 |
| 337 | Results of an open label feasibility study of sodium valproate in people with McArdle disease. Neuromuscular Disorders, 2020, 30, 734-741. | 0.3 | 3 |
| 338 | Myopathy can be a key phenotype of membrin (GOSR2) deficiency. Human Mutation, 2021, 42, 1101-1106. | 1.1 | 3 |
| 339 | Late-onset MADD: a rare cause of cirrhosis and acute liver failure?. Acta Myologica, 2020, 39, 19-23. | 1.5 | 3 |
| 340 | Axial muscle involvement in patients with limb girdle muscular dystrophy type <scp>R9</scp>. Muscle and Nerve, 2022, 65, 405-414. | 1.0 | 3 |
| 341 | Novel truncating variants in <scp>FGD1</scp> detected in two Danish families with <scp>Aarskogâ€“Scott</scp> syndrome and myopathic features. American Journal of Medical Genetics, Part A, 2022, 188, 2251-2257. | 0.7 | 3 |
| 342 | Metabolic myopathies: Defects of carbohydrate and lipid metabolism. , 0, , 390-408. | | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 343 | Vacuoles, Often Containing Glycogen, Are a Consistent Finding in Hypokalemic Periodic Paralysis. Journal of Neuropathology and Experimental Neurology, 2020, 79, 1127-1129. | 0.9 | 2 |
| 344 | Responsiveness of outcome measures in myotonic dystrophy type 1. Annals of Clinical and Translational Neurology, 2020, 7, 1382-1391. | 1.7 | 2 |
| 345 | Contractile properties are impaired in congenital myopathies. Neuromuscular Disorders, 2020, 30, 649-655. | 0.3 | 2 |
| 346 | Function, structure and quality of striated muscles in the lower extremities in patients with late onset Pompe Diseaseâ€"an MRI study. PeerJ, 2021, 9, e10928. | 0.9 | 2 |
| 347 | Patients With Becker Muscular Dystrophy Have Severe Paraspinal Muscle Involvement. Frontiers in Neurology, 2021, 12, 613483. | 1.1 | 2 |
| 348 | Autophagy is affected in patients with hypokalemic periodic paralysis: an involvement in vacuolar myopathy?. Acta Neuropathologica Communications, 2021, 9, 109. | 2.4 | 2 |
| 349 | E-Health & Innovation to Overcome Barriers in Neuromuscular Diseases. Report from the 1st eNMD Congress: Nice, France, March 22-23, 2019. Journal of Neuromuscular Diseases, 2021, 8, 743-754. | 1.1 | 2 |
| 350 | Impaired fat oxidation during exercise in multiple acyl-CoA dehydrogenase deficiency. JIMD Reports, 2019, 46, 79-84. | 0.7 | 2 |
| 351 | Extreme Hypoxia Causing Brady-Arrythmias During Apnea in Elite Breath-Hold Divers. Frontiers in Physiology, 2021, 12, 712573. | 1.3 | 2 |
| 352 | Three novel FHL1 variants cause a mild phenotype of Emeryâ€Dreifuss muscular dystrophy. Human Mutation, 2022, 43, 1234-1238. | 1.1 | 2 |
| 353 | P3.60 Pompe disease in persons with unclassified Limb-girdle muscular dystrophy. Neuromuscular Disorders, 2011, 21, 700-701. | 0.3 | 1 |
| 354 | T.P.47 Bezafibrate does not improve fat oxidation in patients with disorders of fat metabolism; a double blind, randomized clinical trial. Neuromuscular Disorders, 2012, 22, 852-853. | 0.3 | 1 |
| 355 | Muscle biopsies off-set normal cellular signaling in surrounding musculature. Neuromuscular Disorders, 2013, 23, 981-985. | 0.3 | 1 |
| 356 | P.16.8 Does endurance training and protein supplementation improve fitness in patients with Facioscapulohumeral Muscle Dystrophy (FSHD)?. Neuromuscular Disorders, 2013, 23, 824-825. | 0.3 | 1 |
| 357 | G.P.245. Neuromuscular Disorders, 2014, 24, 890. | 0.3 | 1 |
| 358 | P70 EUROMAC: Disease registry for McArdle disease and other pure muscle glycogenolytic disorders presenting with exercise intolerance. Neuromuscular Disorders, 2014, 24, S25. | 0.3 | 1 |
| 359 | Sodium valproate for McArdle disease (glycogen storage disease type V â€" GSDV). Neuromuscular Disorders, 2015, 25, S220-S221. | 0.3 | 1 |
| 360 | Muscle strength relative to cross-sectional area in hypertrophic calf muscles of patients affected by limb girdle type 2I and Becker muscular dystrophies. Neuromuscular Disorders, 2015, 25, S234. | 0.3 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 361 | Testâ€“retest reliability of the 2- and 6-minute walk tests in patients with neuromuscular diseases. Neuromuscular Disorders, 2015, 25, S273. | 0.3 | 1 |
| 362 | Polymyositis following autologous haematopoietic stem cell transplantation. Scandinavian Journal of Rheumatology, 2016, 45, 429-431. | 0.6 | 1 |
| 363 | Autophagy impairment in muscle biopsies from debranching enzyme deficiency (GSDIII) patients: pinpointing novel therapeutic perspectives. Neuromuscular Disorders, 2017, 27, S205-S206. | 0.3 | 1 |
| 364 | Remodel mitochondria and get energized. Neurology, 2018, 90, 633-634. | 1.5 | 1 |
| 365 | Altered somatosensory neurovascular response in patients with Becker muscular dystrophy. Brain and Behavior, 2018, 8, e00985. | 1.0 | 1 |
| 366 | Impaired Fat Oxidation During Exercise in Long-Chain Acyl-CoA Dehydrogenase Deficiency Patients and Effect of IV-Glucose. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3610-3613. | 1.8 | 1 |
| 367 | EP.54Assessment of trunk muscle strength in patients with muscular dystrophies using stationary and hand-held dynamometry: a test-retest reliability study. Neuromuscular Disorders, 2019, 29, S116-S117. | 0.3 | 1 |
| 368 | The Pathophysiology of Exercise and Effect of Training in Mitochondrial Myopathies. , 2019, , 331-348. | | 1 |
| 369 | Energy metabolism during exercise in patients with Î²â€enolase deficiency ( GSDXIII ). JIMD Reports, 2021, 61, 60-66. | 0.7 | 1 |
| 370 | Progression or Not â€“ A Small Natural History Study of Genetical Confirmed Congenital Myopathies. Journal of Neuromuscular Diseases, 2021, 8, 647-655. | 1.1 | 1 |
| 371 | No effect of triheptanoin in patients with phosphofructokinase deficiency. Neuromuscular Disorders, 2022, , . | 0.3 | 1 |
| 372 | M.P.3.09 Lactate is fuel for working muscle in patients with mitochondrial myopathy. Neuromuscular Disorders, 2007, 17, 829-830. | 0.3 | 0 |
| 373 | G.P.14.06 There is no correlation between muscle strength and myotonia in patients with myotonic dystrophy type 1. Neuromuscular Disorders, 2007, 17, 855-856. | 0.3 | 0 |
| 374 | M.P.4.08 Are oxidative capacity and glycolysis affected in X-linked phosphorylase b kinase deficiency?. Neuromuscular Disorders, 2007, 17, 861. | 0.3 | 0 |
| 375 | P3.3 Does muscle strength deteriorate over time in Spinal muscular atrophy type II and III? Fifteen years follow up study in 22 patients with SMA II and 9 patients with SMA III. Neuromuscular Disorders, 2011, 21, 682-683. | 0.3 | 0 |
| 376 | T.P.36 Hepatocyte growth factor reverses atrophy by inducing protein synthesis in mice. Neuromuscular Disorders, 2012, 22, 863. | 0.3 | 0 |
| 377 | G.P.114 Exercise intolerance in Debrancher deficiency is caused by a block in skeletal muscle and liver glycogen breakdown. Neuromuscular Disorders, 2012, 22, 889-890. | 0.3 | 0 |
| 378 | Response letter to â€œCardiac involvement in myotonic dystrophy type 1 â€" Do not forget the loop recorder!â€• International Journal of Cardiology, 2013, 168, 1541. | 0.8 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 379 | P.18.7 Endocrine function in patients with myotonic dystrophy type 1â€“9 year follow-up. Neuromuscular Disorders, 2013, 23, 834. | 0.3 | 0 |
| 380 | Altered somatosensory neurovascular coupling in patients with becker muscular dystrophy. Journal of the Neurological Sciences, 2013, 333, e459. | 0.3 | 0 |
| 381 | Response. Neuromuscular Disorders, 2013, 23, 193. | 0.3 | 0 |
| 382 | Cardiac fibrosis in myotonic dystrophy type 1; an early marker of cardiac involvement. European Heart Journal, 2013, 34, P2987-P2987. | 1.0 | 0 |
| 383 | G.P.320. Neuromuscular Disorders, 2014, 24, 918. | 0.3 | 0 |
| 384 | Differences in genetic defects and morphology of eye- and limb muscles in mitochondrial myopathy. Acta Ophthalmologica, 2015, 93, e306-e308. | 0.6 | 0 |
| 385 | PGM1 deficiency â€“ A heterogeneous myopathy with opportunities for treatment. Neuromuscular Disorders, 2015, 25, S188-S189. | 0.3 | 0 |
| 386 | Application of exome sequencing technologies: A case study of patients with unexplained limb-girdle muscle weakness harbouring GAA mutations. Neuromuscular Disorders, 2016, 26, S108-S109. | 0.3 | 0 |
| 387 | Aerobic anti-gravity exercise in patients with Charcot-Marie-Tooth disease. Types: a pilot study. Neuromuscular Disorders, 2017, 27, S147. | 0.3 | 0 |
| 388 | The EUROMAC registry for rare glycogen storage diseases: preliminary report. Neuromuscular Disorders, 2017, 27, S203-S204. | 0.3 | 0 |
| 389 | P.69NEO1 and NEO-EXT studies: exploratory efficacy of repeat avalglucosidase alfa dosing for up to 5 years in participants with late-onset Pompe disease (LOPD). Neuromuscular Disorders, 2019, 29, S60-S61. | 0.3 | 0 |
| 390 | P.375Does rhythmic auditory stimulation influence walking speed in the 6-minute walk test in patients with myasthenia gravis?. Neuromuscular Disorders, 2019, 29, S190-S191. | 0.3 | 0 |
| 391 | NEO1 and NEO-EXT studies: Long-term safety of repeat avalglucosidase alfa dosing for 4.5 years in late-onset Pompe disease patients. Molecular Genetics and Metabolism, 2019, 126, S115-S116. | 0.5 | 0 |
| 392 | MUSCLE IMAGING â€“ MRI. Neuromuscular Disorders, 2020, 30, S95-S96. | 0.3 | 0 |
| 393 | Editorial: Remaining diagnostic issues and start of a treatment era for muscle diseases. Current Opinion in Neurology, 2020, 33, 587-589. | 1.8 | 0 |
| 394 | Effects of rhythmic auditory stimulation on walking during the 6-minute walk test in patients with generalised Myasthenia Gravis. European Journal of Physiotherapy, 0, , 1-000. | 0.7 | 0 |
| 395 | Combined Muscle Biopsy and Comprehensive Electrophysiology in General Anesthesia is Valuable in Diagnosis of Neuromuscular Disease in Children. Neuropediatrics, 2021, 52, 462-468. | 0.3 | 0 |
| 396 | Plasma lactate responses during and after submaximal handgrip exercise are not diagnostically helpful in mitochondrial myopathy. Mitochondrion, 2021, 60, 21-26. | 1.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 397 | METABOLIC MYOPATHIES. Neuromuscular Disorders, 2021, 31, S111-S112. | 0.3 | 0 |
| 398 | LGMD. Neuromuscular Disorders, 2021, 31, S103. | 0.3 | 0 |
| 399 | LGMD. Neuromuscular Disorders, 2021, 31, S107-S108. | 0.3 | 0 |
| 400 | European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. Nervno-Myshechnye Bolezni, 2019, 8, 19-34. | 0.2 | 0 |
| 401 | Growth Factors Do Not Improve Muscle Function in Young or Adult mdx Mice. Biomedicines, 2022, 10, 304. | 1.4 | 0 |